Compare HTOO & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTOO | EDSA |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | Ireland | Canada |
| Employees | 131 | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 7.5M |
| IPO Year | N/A | 2018 |
| Metric | HTOO | EDSA |
|---|---|---|
| Price | $3.36 | $2.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 18.2K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4,832.46 | N/A |
| Revenue Next Year | $81.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.15 | $0.72 |
| 52 Week High | $12.63 | $2.95 |
| Indicator | HTOO | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 73.44 |
| Support Level | $3.27 | $1.87 |
| Resistance Level | $4.26 | $2.53 |
| Average True Range (ATR) | 0.22 | 0.27 |
| MACD | 0.02 | 0.12 |
| Stochastic Oscillator | 31.26 | 79.84 |
Fusion Fuel Green PLC is a provider of full-service energy engineering and advisory solutions, specializing in green hydrogen and industrial gas applications. It offers a broad portfolio of services, including the design, supply, installation, and maintenance of energy systems, as well as the transport and distribution of liquefied petroleum gas. The company serves a diverse customer base spanning commercial buildings, mixed-use developments, heavy industries, and food service sectors. The group currently derives revenue by providing comprehensive solutions for the liquefied petroleum gas (LPG) industry, which includes the supply, installation, and maintenance of LPG systems, as well as transportation and delivery of LPG in both bulk and cylinder formats.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.